September 23, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2515005

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

Listen to this summary

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli, Stefania Galimberti, Shanmuganathan Chandrakasan, Federico Fraschetta, Carmen Caputo, Davide Sala, Ilaria Monti, Federica Barzaghi, Valeria Calbi, Daniele Canarutto, Giulia Consiglieri, Matteo Doglio, Francesca Fumagalli, Vera Gallo, Maddalena Migliavacca, Salvatore Recupero, Francesca Tucci, Alessia Orsini, Raffaella Milani, Mariam Datukishvili, Simona De Gregori, Eugenio Montini, Paolo Silvani, Matias Soncini, Elena Tomasetto, Koen van Rossem, Laura Castagnaro, Federica Miotto, Stefano Zancan, Celeste Scotti, Sean Russell, Luigi Naldini, Fabio Ciceri, Maria Ester Bernardo, Suhag Parikh, Maria Pia Cicalese, Alessandro Aiuti, WAS Gene Therapy Group

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play